INSM Stock Risk & Deep Value Analysis
Insmed Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on INSM
We analyzed Insmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INSM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when INSM moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈INSM Performance Overview3yr weekly
Unlock INSM Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
INSM Quality Rating
INSM Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
About Insmed Inc (INSM)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
large
Market Cap
$35.54B
INSM Deep Value Analysis
INSM Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
Compare INSM to Similar Stocks
See how Insmed Inc stacks up against related companies in our head-to-head analysis.
INSM Red Flags & Warning Signs
- ⚠
Slower-than-expected BRINSUPRI commercial uptake or reimbursement challenges
- ⚠
Negative clinical trial results for TPIP or ARIKAYCE sNDA rejection
- ⚠
Continued significant EPS misses leading to prolonged cash burn concerns
Unlock INSM Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
INSM Financial Health Metrics
Market Cap
$35.54B
P/E Ratio
-25.72
Profit Margin
-210.54%
Debt-to-Equity
0.76
Dividend Yield
0.00%
Beta (Volatility)
1.10
Earnings Per Share
$-5.93
INSM Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to patent protection on innovative therapies and high barriers to entry in rare disease drug development and regulatory approval. Once established, therapies for chronic conditions often exhibit high switching costs for patients and prescribers.
INSM Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
INSM Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Continued BRINSUPRI U.S. launch momentum & Q1 2026 earnings results (expected late April/early May 2026)
- •Further updates on prescriber adoption and market penetration for BRINSUPRI
Medium-Term (6-18 months)
- •H2 2026: sNDA filing for ARIKAYCE based on ENCORE Phase 3b data (label expansion)
- •H2 2026: Initiation of late-stage study for TPIP in Idiopathic Pulmonary Fibrosis (IPF)
- •Potential regulatory milestones for BRINSUPRI in ex-U.S. markets
Long-Term (18+ months)
- •TPIP clinical trial progression and potential future market entry for IPF
- •Expansion of BRINSUPRI into additional indications beyond NCFBE
- •Establishing market leadership in NCFBE and competitive positioning in IPF
Catalysts & Growth Drivers
Sign up free to see growth catalysts
INSM Bull Case: What Could Go Right
- ✓
Acceleration in BRINSUPRI sales exceeding analyst estimates
- ✓
Positive updates on TPIP Phase 3 enrollment and progress
- ✓
Improvement in operating margins or a clear communicated path to profitability
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Insmed Inc (INSM)?
As of April 7, 2026, Insmed Inc has a DVR Score of 7.3 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Insmed Inc?
Insmed Inc's market capitalization is approximately $35.5B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Insmed Inc use?
INSM is the ticker symbol for Insmed Inc. The company trades on the NMS.
What is the risk level for INSM stock?
Our analysis rates Insmed Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of INSM?
Insmed Inc currently has a price-to-earnings (P/E) ratio of -25.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Insmed Inc's revenue growing?
Insmed Inc has reported revenue growth of 152.6%. The company is showing strong top-line momentum.
Is INSM stock profitable?
Insmed Inc has a profit margin of -210.5%. The company is currently unprofitable.
How often is the INSM DVR analysis updated?
Our AI-powered analysis of Insmed Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.